Association between D-dimers and in-hospital all-cause mortality in COVID-19 patients at a tertiary hospital in South Africa: A retrospective study
Article Sidebar
Main Article Content
Abstract
Background. The COVID‐19 pandemic was caused by the SARS‐CoV‐2 virus. Many studies have shown that D‐dimer levels were elevated in patients hospitalised for severe COVID‐19, and that they served as a marker of poor prognosis with increased mortality in this subpopulation. There is a paucity of data on the prognostic value of D‐dimer levels during the COVID‐19 pandemic in the African population.
Objectives. To investigate the relationship between elevated D‐dimer levels on admission and in‐hospital mortality associated with COVID‐19. The study also examined the sociodemographics of the study population, clinical characteristics, length of hospital stay and outcomes, stratified by D‐dimer levels.
Methods. A retrospective observational review of COVID‐19 patients admitted via acute medical admissions at Livingstone Tertiary Hospital, Gqeberha, South Africa, was conducted between 1 October 2020 and 30 September 2021, using the national COVID‐19 hospital surveillance (DATCOV) database. D‐dimer levels that were measured within 48 hours of admission and patient outcomes (discharge and in‐hospital all‐cause mortality) were analysed. Statistical significance was set at p<0.05.
Results. Of 423 patients with COVID‐19, 267 (63.1%) had elevated D‐dimer levels (>0.5 μg/mL) and 156 (36.9%) had normal D‐dimer levels (≤0.5 μg/mL). Of the 267 with elevated D‐dimer levels, 113 (42.3%) died during their hospital stay, whereas of the 156 with normal D‐dimer levels, 38 (24.4%) died in hospital. D‐dimer levels ≥1.1 μg/mL were associated with increased in‐hospital all‐cause mortality (odds ratio (OR) 2.717; p<0.001). Patients with D‐dimer levels between 1.1 and 2 μg/mL were 2.3 times more likely to die in hospital compared with patients who had a normal D‐dimer level (OR 2.311; p=0.005), and patients with D‐dimer levels >2.0 μg/mL were three times more likely to die in hospital compared with patients with levels ≤0.5 μg/mL (OR 3.047; p<0.001). Apart from elevated D‐dimer levels, age ≥70 years (OR 4.112; p<0.001), the presence of at least one comorbidity (OR 3.638; p<0.001), and specifically hypertension as a comorbidity (OR 3.224; p<0.001), were also found to be significantly associated with increased in‐hospital COVID‐19 mortality.
Conclusion. Elevated D‐dimer levels on admission were associated with increased COVID‐19 in‐hospital all‐cause mortality (OR 2.279; p<0.001).
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Chilimuri S, Sun H, Alemam A, et al. Predictors of mortality in adults admitted with COVID‐19: Retrospective cohort study from New York City. West J Emerg Med 2020;21(4):779‐784. https://doi.org/10.5811/westjem.2020.6.47919
2. Shah S, Shah K, Patel SB, et al. Elevated D‐dimer levels are associated with increased risk of mortality in coronavirus disease 2019: A systematic review and meta‐analysis. Cardiol Rev 2020;28(6):295‐302. https://doi.org/10.1097/CRD.0000000000000330
3. Yao Y, Cao J, Wang Q, et al. D‐dimer as a biomarker for disease severity and mortality in COVID‐19 patients: A case‐control study. J Intensive Care 2020;8:49. https://doi. org/10.1186/s40560‐020‐00466‐z
4. World Health Organization. WHO COVID‐19 dashboard. https://covid19.who.int (accessed 30 January 2022).
5. South African Medical Research Council. Report on weekly deaths in South Africa. 2022. https://www.samrc.ac.za/reports/report‐weekly‐deaths‐south‐africa (accessed 27 May 2022).
6. Shi L, Wang Y, Wang YD, Duan GC, Yang HY. D‐dimer is associated with the risk of mortality in coronavirus disease 2019 patients. Eur Rev Med Pharmacol Sci 2020;24(16):8576‐8579. https://doi.org/10.26355/eurrev_202008_22655
7. Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D‐dimer level is a useful predictor for mortality in patients with COVID‐19: Analysis of 483 cases. Diabetes Metab Syndr 2020;14(6):2245‐2249. https://doi.org/10.1016/j.dsx.2020.11.007
8. Nugroho J, Wardhana A, Maghfirah I, et al. Relationship of D‐dimer with severity and mortality in SARS‐CoV‐2 patients: A meta‐analysis. Int J Lab Haematol 2021;43(1):110‐115. https://doi.org/10.1111/ijlh.13336
9. Allwood BW, Koegelenberg CF, Ngah VD, et al. COVID‐19 Research Response Collaboration. Predicting COVID‐19 outcomes from clinical and laboratory parameters in an intensive care facility during the second wave of the pandemic in South Africa. IJID Reg 2022;3:242‐247. https://doi.org/10.1016/j.ijregi.2022.03.024
10. Martín‐Rojas RM, Pérez‐Rus G, Delgado‐Pinos VE, et al. COVID‐19 coagulopathy: An in‐depth analysis of the coagulation system. Eur J Haematol 2020;105(6):741‐750. https://doi.org/10.1111/ejh.13501
11. Cabrera‐GarciaD,MiltiadesA,YimP,etal.Plasmabiomarkersassociatedwithsurvival and thrombosis in hospitalised COVID‐19 patients. Int J Hematol 2022;116(6):937‐ 946. https://doi.org/10.1007/s12185‐022‐03437‐2
12. Cordon‐Cardo C, Pujadas E, Wajnberg A, et al. COVID‐19: Staging of a new disease. Cancer Cell 2020;38(5):594‐597. https://doi.org/10.1016/j.ccell.2020.10.006
13. Huang Y, Lyu X, Li D, et al. A cohort study of 676 patients indicates that D‐dimer is a critical risk factor for the mortality of COVID‐19. PLoS ONE 2020;15(11):e0242045. https://doi.org/10.1371/journal.pone.0242045
14. BansalA,SinghAD,JainV,etal.TheassociationofD‐dimerswithmortality,intensive care unit admission or acute respiratory distress syndrome in patients hospitalized with coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis. Heart Lung 2021;50(1):9‐12. https://doi.org/10.1016/j.hrtlng.2020.08.024
15. Naymagon L, Zubizarreta N, Feld J, et al. Admission D‐dimer levels, D‐dimer trends, and outcomes in COVID‐19. Thromb Res 2020;196:99‐105. https://doi.org/10.1016/j. thromres.2020.08.032
16. Oualim S, Abdeladim S, Ouarradi AE, et al. Elevated levels of D‐dimer in patients with COVID‐19: Prognosis value. Pan Afr Med J 2020;35(Suppl 2):105. https://doi. org/10.11604/pamj.supp.2020.35.2.24692
17. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID‐19 pneumonia caused by SARS‐CoV‐2: A prospective cohort study. Eur Respir J 2020;55(5):2000524. https://doi.org/10.1183/13993003.00524‐2020
18. Zhang L, Yan X, Fan Q, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with COVID‐19. J Thromb Haemost 2020;18(6):1324‐1329. https://doi.org/10.1111/jth.14859
19. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30‐day mortality in patients hospitalised with COVID‐19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol Res 2020;158:104931. https://doi.org/10.1016/j.phrs.2020.104931
20. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395(10229):1054‐1062. https://doi.org/10.1016/S0140‐6736(20)30566‐3
21. Hodges G, Pallisgaard J, Schjerning Olsen AM, et al. Association between biomarkers and COVID‐19 severity and mortality: A nationwide Danish cohort study. BMJ Open 2020;10(12):e041295. https://doi.org/10.1136/bmjopen‐2020‐041295